NextTrip Reported In-line with Estimates

NextTrip (NTRP) reported a loss of $0.22 per share on revenue of $1.45 million for the fiscal first quarter ended May 2026. The consensus estimate was a loss of $0.22 per share. The company reported in-line with consensus estimates while revenue grew 944.60% on a year-over-year basis.

Neurotrope Inc is a development stage company. The Company is a clinical stage biopharmaceutical and diagnostics company, engaged in developing drug candidate called bryostatin and a diagnostic test for Alzheimer’s Disease.